SIGMA-SYSTEMS
4.6.2019 10:02:18 CEST | Business Wire | Press release
Sigma Systems, the global leader in catalog-driven software, is pleased to announce that it has secured a deal to drive the next generation of digital services for one of the largest services providers in Brazil, in partnership with Engineering Do Brasil, a leading IT services provider and a subsidiary of Engineering Ingegneria Informatica S.p.A.
A new digital environment will be created to enable the rapid introduction and seamless selling of new digital offerings to customers across the country. Under the three-year agreement, Sigma Systems, in partnership with Engineering Do Brasil, will provide Sigma CPQ and Sigma Catalog to support the enablement of this new digital infrastructure, thus facilitating a greater level of agility and faster time-to-market for new products and offerings.
Tim Spencer, President and CEO, Sigma Systems, commented : “As a global software provider focused on enabling service providers to innovate quickly and launch new products and services, we are well-placed to support the needs of today’s digital consumer. In partnership with Engineering Do Brasil, we are confident that Sigma Catalog and Sigma CPQ will play a major role in unlocking new opportunities, as it delivers an array of new digital products and services for customers across the country.”
Sigma CPQ (Configure Price Quote), included in the latest edition of the Gartner Magic Quadrant for CPQ , is a telecom-specific, omni-channel quote and order-capture product that enables service providers to sell products, from standardized consumer offerings to complex tailored enterprise services. Deployed in the cloud or on-premise, Sigma CPQ increases the speed and improves the accuracy of sales quotes and orders with an immediate effect on sales efficiency, agility and customer satisfaction.
Deployed in the cloud or on-premise, Sigma Catalog accelerates product innovation to increase revenue from new digital products and new business models.
For further information about Sigma Systems, its award-winning Create-Sell-Deliver portfolio , and getting Next Done NowTM visit sigma-systems.com, or contact us on info@sigma-systems.com .
About Sigma Systems (Twitter @SigmaSystems)
Sigma Systems is the global leader in catalog-driven software solutions for communications, media, and high-tech companies. It serves over 80 customers in 40 countries with its award-winning products. The company’s portfolio spans enterprise-wide Catalog, Configure Price Quote (CPQ), Order Management, Provisioning, Insights and Portfolio Inventory products, and offers a core set of services including professional services, cloud services, and managed services. Sigma utilizes an agile approach to implementing its B/OSS products for its customers. Sigma has offices in North and South America, Europe and Asia Pacific, with technology and integration partners globally.
Additional information can be found online at https://sigma-systems.com/
About Engineering Do Brasil
Engineering Do Brasil is a Consulting and Information Technology global company specialized in Digital Transformation. Through Digital Transformation, Business Integration, Consulting and Outsourcing, Engineering Do Brasil transforms its customers’ operational processes compatible with those of the Digital Era. With more than 39 years of experience in the IT market, more than 10 thousand professionals and projects on more than 10 thousand large customers across various market segments, the experience of our group is being continuously improved by the investment in R&D, with more than 250 researchers, besides several partnerships with the main research centers and universities around the world. More information: https://www.eng.it/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190604005371/en/
Contact:
Adnan Bashir Senior Corporate Communications Manager Sigma Systems +1 647-204-0999
Chloe Purcell Head of PR Milner Strategic Marketing Ltd. +44 1473 633123
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom